作者
Matthias Daniel Zink, Winnie Chua, Stef Zeemering, Luigi Di Biase, Bayes de Luna Antoni, Callans David, Gerhard Hindricks, Karl Georg Haeusler, Hussein R Al-Khalidi, Jonathan P Piccini, Lluís Mont, Jens Cosedis Nielsen, Luis Alberto Escobar, Joseph De Bono, Isabelle C Van Gelder, Tom De Potter, Daniel Scherr, Sakis Themistoclakis, Derick Todd, Paulus Kirchhof, Ulrich Schotten
发表日期
2020/9
期刊
EP Europace
卷号
22
期号
9
页码范围
1337-1344
出版商
Oxford University Press
简介
Aims
Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50–70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation.
Methods and results
We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA–AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced …
学术搜索中的文章
MD Zink, W Chua, S Zeemering, L Di Biase, BL Antoni… - EP Europace, 2020